AcelRx Pharma (ACRX) Commences ARX-04 Phase 3 in Moderate-to-Severe Acute Pain
Tweet Send to a Friend
AcelRx Pharma (NASDAQ: ACRX) announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
